Novartis is the first pharmaceutical company to provide a targeted therapeutic treatment for PIK3CA conditions.
Providing entertainment and fun for our 2024 conference
Page last updated August 3, 2024
Use this form to let us know if you are having difficulty with something on our website, or just to provide general feedback. This form will report your browser, device, and logged-in status to us along with your feedback.